LAVA Therapeutics NV Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Lava Therapeutics NV |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
Related Tickers: LVTX
TL;DR
LAVA Therapeutics Q1 2025 10-Q filed. Financials updated, severance costs noted.
AI Summary
LAVA Therapeutics NV filed its 10-Q for the period ending March 31, 2025. The company reported financial data for the first quarter of 2025, including details on common stock, retained earnings, and additional paid-in capital. Specific expense figures, such as employee severance costs, were also noted for the first quarter of 2025.
Why It Matters
This filing provides investors with an update on LAVA Therapeutics' financial health and operational expenses for the first quarter of 2025, crucial for assessing the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine quarterly report and does not contain significant new risk factors or material adverse events.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial data)
- 2025-03-31 — Balance Sheet Date (End of the first quarter of 2025)
Key Players & Entities
- LAVA Therapeutics NV (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- 001-40241 (dollar_amount) — SEC file number
FAQ
What were LAVA Therapeutics NV's retained earnings as of March 31, 2025?
As of March 31, 2025, LAVA Therapeutics NV's retained earnings are listed in the filing.
What is the SEC file number for LAVA Therapeutics NV?
The SEC file number for LAVA Therapeutics NV is 001-40241.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
Were there any employee severance expenses reported for the first quarter of 2025?
Yes, employee severance expenses are noted for the period of January 1, 2025, to March 31, 2025.
When was LAVA Therapeutics NV incorporated?
The state of incorporation for LAVA Therapeutics NV is P7, with a fiscal year end of 1231.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding LAVA Therapeutics NV.